Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   15/10/2025
137,73 USD (+0,36%)
(+0,36%)   15/10/2025

7 oktober 2025 · Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results · Persbericht

6 oktober 2025 · Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise · Persbericht

6 oktober 2025 · Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea · Persbericht

23 september 2025 · Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden · Persbericht

22 september 2025 · Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder · Persbericht

16 september 2025 · Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 · Persbericht

26 augustus 2025 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in September · Persbericht

6 augustus 2025 · Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference · Persbericht

30 juli 2025 · Neurocrine Biosciences Reports Second Quarter 2025 Financial Results · Persbericht

15 juli 2025 · Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition · Persbericht

15 juli 2025 · Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 · Persbericht

14 juli 2025 · Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting · Persbericht

14 juli 2025 · Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025 · Persbericht

9 juli 2025 · Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results · Persbericht

30 juni 2025 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist · Persbericht

27 juni 2025 · Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea · Persbericht

20 juni 2025 · Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia · Persbericht

9 juni 2025 · Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer · Persbericht

2 juni 2025 · Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia · Persbericht

28 mei 2025 · Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 · Persbericht

Mijn selecties